1. Home
  2. ADNT vs NVAX Comparison

ADNT vs NVAX Comparison

Compare ADNT & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adient plc

ADNT

Adient plc

HOLD

Current Price

$19.53

Market Cap

1.5B

ML Signal

HOLD

Logo Novavax Inc.

NVAX

Novavax Inc.

HOLD

Current Price

$6.75

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADNT
NVAX
Founded
2016
1987
Country
Ireland
United States
Employees
N/A
N/A
Industry
Auto Parts:O.E.M.
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.1B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
ADNT
NVAX
Price
$19.53
$6.75
Analyst Decision
Hold
Hold
Analyst Count
10
8
Target Price
$21.90
$9.75
AVG Volume (30 Days)
1.2M
3.3M
Earning Date
01-27-2026
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
2.07
Revenue
$14,535,000,000.00
$1,064,651,000.00
Revenue This Year
$1.36
$58.91
Revenue Next Year
$2.11
N/A
P/E Ratio
N/A
$3.22
Revenue Growth
N/A
20.27
52 Week Low
$10.04
$5.01
52 Week High
$26.16
$11.55

Technical Indicators

Market Signals
Indicator
ADNT
NVAX
Relative Strength Index (RSI) 48.30 43.34
Support Level $18.67 $6.36
Resistance Level $19.96 $6.76
Average True Range (ATR) 0.67 0.22
MACD 0.21 0.05
Stochastic Oscillator 64.84 47.39

Price Performance

Historical Comparison
ADNT
NVAX

About ADNT Adient plc

Adient began trading Oct. 31, 2016, when Johnson Controls spun off its automotive experience segment. Adient is a leading seating supplier to the industry with about a midteens share of the global market including unconsolidated joint venture business. Its share in China is around 20%, down from about 45%, following the sale of its main joint venture there at the end of fiscal 2021. Unconsolidated revenue from joint ventures was about $3.5 billion in fiscal 2025 and consolidated China revenue was $1.3 billion. The company is headquartered in Ireland but has corporate offices in the Detroit area. Fiscal 2025 (Sept. 30 year-end) consolidated revenue, which excludes joint venture sales, was $14.5 billion.

About NVAX Novavax Inc.

Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.

Share on Social Networks: